Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 3/20 | 0.47 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.46 |
| ▸ | RBP4 | P02753 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3249046 | 0.92 | EPHX2 (0.46) | EPHX2HRH3 | |
| SCHEMBL3239252 | 0.87 | HRH3 (0.43) | HRH3 | |
| SCHEMBL3238665 | 0.86 | HRH3 (0.44) | HRH3 | |
| SCHEMBL3238714 | 0.86 | HRH3 (0.43) | HRH3 | |
| SCHEMBL3245125 | 0.86 | EPHX2 (0.47) | EPHX2HRH3 | |
| SCHEMBL3243905 | 0.85 | HRH3 (0.42) | ALDH1A1HRH3 | |
| SCHEMBL3244114 | 0.84 | CYP2D6 (0.46) | HPGDHRH3 | |
| SCHEMBL3242464 | 0.83 | HRH3 (0.42) | ALDH1A1KMT2AHRH3MAPT | |
| SCHEMBL3245132 | 0.83 | PRKAA2 (0.44) | HRH3 | |
| SCHEMBL3244946 | 0.81 | HRH3 (0.47) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069331-B1 | 1H-INDOL-6-YL-PIPERAZIN-1-YL-METHANONE-DERIVATIVES FOR USE AS H3 RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | claimed |
| CN-101490039-A | 1H-indol-6-yl-piperazin-1-yl-methanone-derivatives for use as H3 receptor modulators | HOFFMANN LA ROCHE (CH) | 2009-07-22 | — | — | CN | claimed |
| EP-2069331-A1 | 1H-INDOL-6-YL-PIPERAZIN-1-YL-METHANONE-DERIVATIVES FOR USE AS H3 RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-06-17 | — | — | EP | claimed |
| US-7514433-B2 | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-04-07 | — | — | US | claimed |
| WO-2008015125-A1 | 1H-INDOL-6-YL-PIPERAZIN-1-YL-METHANONE-DERIVATIVES FOR USE AS H3 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-07 | — | — | WO | claimed |
| US-20080032976-A1 | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-07 | — | — | US | claimed |
| EP-2069331-B1 | 1H-INDOL-6-YL-PIPERAZIN-1-YL-METHANONE-DERIVATIVES FOR USE AS H3 RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | disclosed |
| CN-101490039-A | 1H-indol-6-yl-piperazin-1-yl-methanone-derivatives for use as H3 receptor modulators | HOFFMANN LA ROCHE (CH) | 2009-07-22 | — | — | CN | disclosed |
| EP-2069331-A1 | 1H-INDOL-6-YL-PIPERAZIN-1-YL-METHANONE-DERIVATIVES FOR USE AS H3 RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-06-17 | — | — | EP | disclosed |
| US-7514433-B2 | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-04-07 | — | — | US | disclosed |
| WO-2008015125-A1 | 1H-INDOL-6-YL-PIPERAZIN-1-YL-METHANONE-DERIVATIVES FOR USE AS H3 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-07 | — | — | WO | disclosed |
| US-20080032976-A1 | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032976-A1 | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives | HTR6, HTR1A, HRH4 | TNF 3999/4885TNFSF11 2895/4885RBP4 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.